NMDA receptor hypofunction model of schizophrenia (Q33813143)

29 July 2017

1 reference

title

NMDA receptor hypofunction model of schizophrenia (English)

1 reference

ORCID Public Data File 2021

29 July 2017

0 references

1 reference

author name string

Olney JW

series ordinal

1

1 reference

29 July 2017

Newcomer JW

series ordinal

2

1 reference

29 July 2017

Farber NB

series ordinal

3

1 reference

29 July 2017

publication date

1 November 1999

1 reference

Journal of Psychiatric Research

29 July 2017

published in

1 reference

29 July 2017

volume

33

1 reference

29 July 2017

issue

6

1 reference

29 July 2017

page(s)

523-533

1 reference

Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Multifocal brain damage induced by phencyclidine is augmented by pilocarpine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Ketamine-iorazepam. Attenuation of psychic sequelae of ketamine by lorazepam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Competitive and noncompetitive NMDA antagonists induce similar limbic degeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Mental illness in adults with fetal alcohol syndrome or fetal alcohol effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

alpha 2 adrenergic agonists prevent MK-801 neurotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Serotonergic Agents That Activate 5HT2A Receptors Prevent NMDA Antagonist Neurotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Glutamatergic regulation of acetylcholine output in different brain regions: a microdialysis study in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

The DARPP-32/protein phosphatase-1 cascade: a model for signal integration1Published on the World Wide Web on 22 January 1998.1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

MK-801 increases endogenous acetylcholine release in the rat parietal cortex: a study using brain microdialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

MK-801-induced neuronal damage in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Hypobaric-ischemic conditions produce glutamate-like cytopathology in infant rat brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Halothane prevents MK-801 neurotoxicity in the rat cingulate cortex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

5-Hydroxytryptamine 2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Recent advances in the phencyclidine model of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Isoflurane and propofol block neurotoxicity caused by MK-801 in the rat posterior cingulate/retrosplenial cortex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-adrenergic agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Interactive effects of subanesthetic ketamine and haloperidol in healthy humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Effects of phencyclidine on excitatory amino acid activation of spinal interneurones in the cat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Effect of thiopentone on emergence reactions to ketamine anaesthesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Effects of Prolonged Infusions of the NMDA Antagonist Aptiganel Hydrochloride (CNS 1102) in Normal Volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

D1 receptor in interneurons of macaque prefrontal cortex: distribution and subcellular localization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Glutamate receptor dysfunction and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

NMDA Antagonist Neurotoxicity: Mechanism and Prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Ketamine: an update on the first twenty-five years of clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Ketamine--its pharmacology and therapeutic uses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Widespread origin of the primate mesofrontal dopamine system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Benzodiazepines in the treatment of schizophrenia: a review and reappraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: potential relevance to Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-3956(99)50029-1

10.1016/S0022-3956(99)00029-1

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference